Efficacy of ultrasound endoscopy with artificial intelligence for the differential diagnosis of non-gastric gastrointestinal stromal tumors

Yosuke Minoda1,2, Eikichi Ihara1,3*, Nao Fujimori1, Shuzaburo Nagatomo1, Mitsuru Esaki1, Yoshitaka Hata1, Xiaopeng Bai1, Yoshimasa Tanaka1, Haruei Ogino1, Takatoshi Chinen1, Qingjiang Hu4, Eiji Oki4, Hidetaka Yamamoto5 & Yoshihiro Ogawa1

Gastrointestinal stromal tumors (GISTs) are common subepithelial lesions (SELs) and require treatment considering their malignant potential. We recently developed an endoscopic ultrasound-based artificial intelligence (EUS-AI) system to differentiate GISTs from non-GISTs in gastric SELs, which were used to train the system. We assessed whether the EUS-AI system designed for diagnosing gastric GISTs could be applied to non-gastric GISTs. Between January 2015 and January 2021, 52 patients with non-gastric SELs (esophagus, n = 15; duodenum, n = 26; colon, n = 11) were enrolled. The ability of EUS-AI to differentiate GISTs from non-GISTs in non-gastric SELs was examined. The accuracy, sensitivity, and specificity of EUS-AI for discriminating GISTs from non-GISTs in non-gastric SELs were 94.4%, 100%, and 86.1%, respectively, with an area under the curve of 0.98 based on the cutoff value set using the Youden index. In the subanalysis, the accuracy, sensitivity, and specificity of EUS-AI were highest in the esophagus (100%, 100%, 100%; duodenum, 96.2%, 100%, 0%; colon, 90.9%, 100%, 0%); the cutoff values were determined using the Youden index or the value determined using stomach cases. The diagnostic accuracy of EUS-AI increased as lesion size increased, regardless of lesion location. EUS-AI based on gastric SELs had good diagnostic ability for non-gastric GISTs.
the gastrointestinal tract are required. Indeed, substantial effort is required to collect non-gastric SEL images, including GISTs, since most SELs (and approximately 70% of gastrointestinal GISTs) occur in the stomach. The first step is to assess whether EUS-AI designed for the diagnosis of gastric GISTs can be applied to non-gastric GISTs. Thus, the objective of the present study was to determine the diagnostic ability of EUS-AI that had been previously created based on gastric SELs for non-gastric SELs.

Results

225 SEL cases was enrolled in this study. 52 patients with non-gastric SEL (15 esophageal, 26 duodenal, and 11 colon), including 20 patients diagnosed by EUS-FNAB or biopsy alone, were used as test cases (Table 1). The median size of the SELs enrolled in this study was 21.5 mm, and the efficacy of EUS-AI, which was constructed using 173 previously reported gastric SELs, was assessed in two test cases: the abovementioned all 52 cases and 32 cases who underwent surgery with postoperative diagnosis of GIST in 31 cases and non-GIST in remaining only one excluding 20 cases being diagnosed by EUS-FNAB or biopsy alone.

When evaluated in all 52 cases, the accuracy, sensitivity, and specificity of EUS-AI for discriminating GISTs from non-GISTs in the gastrointestinal tract other than the stomach were 94.4%, 100%, and 86.1%, respectively. The receiver operating characteristic curve of EUS-AI for the diagnosis of non-gastric GISTs and its AUC (0.98, high accuracy) are shown in Fig. 1. When evaluated in 32 cases where the final pathology diagnosis was made with surgical specimens, the accuracy, sensitivity, and specificity of EUS-AI was 96.9%, 100%, and 0%, respectively, and its AUC was 0.90 (high accuracy). The null specificity was obtained because only one of non-GIST cases underwent surgery in this study population. In contrast, the diagnostic accuracy of EUS-FNAB was 100% for the 29 patients who underwent surgery after preoperative diagnosis had been made by EUS-FNAB.

In the subanalysis, the diagnostic abilities of EUS-AI for non-gastric GISTs in the esophagus, duodenum, and colon is analyzed using the abovementioned all 52 cases and summarized in Table 2. The accuracy, sensitivity, and specificity of EUS-AI for distinguishing GISTs from non-GISTs were 100%, 100%, and 0%, respectively, in the esophagus, 96.2%, 100%, and 0%, respectively, in the duodenum, and 90.9%, 100%, and 0%, respectively, in the colon based on the cutoff value set for each part of the gastrointestinal tract using the Youden index (Table 3). There was no difference in diagnostic accuracy and sensitivity for non-gastric GISTs in the esophagus, duodenum, and colon between the abovementioned Youden index and the cutoff value of 0.94 set for the stomach as previously reported. The AUC for the diagnostic ability of EUS-AI for non-gastric GISTs including the esophagus, duodenum, and colon were 1.0 (high accuracy), 0.96 (high accuracy), and 0.80 (moderate accuracy), respectively (Table 3).

SEL cases that were incorrectly diagnosed by EUS-AI. Three cases were incorrectly diagnosed by EUS-AI as follows: esophageal leiomyoma 15 mm in size with mixed hypoechoic and hypoechoic features on EUS, duodenal aberrant pancreas (Fig. 1B), and colonic appendiceal myxoma (Fig. 1C).

Relationship between the diagnostic accuracy of EUS-AI for non-gastric GISTs and lesion size. The relationship between the diagnostic accuracy of EUS-AI and lesion size is shown in Fig. 2A. The diagnostic accuracy of EUS-AI increased as the lesion size increased, regardless of the lesion location (Fig. 2B).

Discussion

This study showed that EUS-AI is useful for the differential diagnosis of GISTs in the gastrointestinal tract other than the stomach, although it was trained for gastric SELs. Furthermore, the cutoff value of EUS-AI for distinguishing between GISTs and non-GISTs in the stomach can also be applied to non-gastric GISTs.

Even including the cases diagnosed by EUS-FNAB or biopsy alone, the diagnostic accuracy and sensitivity of EUS-AI for non-gastric GISTs were 90%–100% and 100%, respectively, which are comparable to those of gastric GISTs (90% for accuracy and 100% for sensitivity) that we previously reported, but also comparable to other AI systems with different algorithms for SELs of the upper gastrointestinal tract. The diagnostic accuracy of EUS-AI for non-gastric GISTs in different parts of the gastrointestinal tract increased with lesion size, which was also consistent with the findings in the stomach, indicating that the diagnostic ability of EUS-AI depends

| Number of cases | 52 |
|-----------------|----|
| Sex, male/female | 33/19 |
| Age, years | 21.5 (32–74) |
| Lesion size, mm | 21.5 (8.0–100) |
| **Histological type and number of cases** | |
| GIST | 36 (93.3%) |
| Leiomyoma | 14 (6.7%) |
| Aberrant pancreas | 1 (3.8%) |
| Appendiceal mucocele | 1 (9.1%) |

Table 1. Patient and lesion characteristics for test cases. Values are presented as n, n (%), or median (range). GIST, gastrointestinal stromal tumors.
on the lesion size regardless of tumor location. In addition, there was no significant difference in the diagnostic accuracy and sensitivity of EUS-AI for non-gastric GISTs between the cutoff value set for different part of the gastrointestinal tract using the Youden index and that of the stomach as we previously determined. These findings suggest that once the EUS-AI system is built to differentiate GISTs from non-GISTs in one part of the gastrointestinal tract, it can be applied to other parts of the gastrointestinal tract.

Interestingly, the diagnostic accuracy of EUS-AI was similar despite the large difference in the frequency of GISTs between the esophagus and other sites. This suggests that the frequency of the disease is not involved in EUS-AI diagnosis; instead, the EUS imaging findings themselves are important in diagnosis. EUS images of GISTs tend to show typical changes such as cystic degeneration with increasing lesion size\textsuperscript{21–23}. It is possible that the accuracy of the EUS-AI system can be further improved by analyzing the pixel pattern of GISTs in the EUS image.

If the EUS-AI system constructed based on gastric SELs is established as the primary diagnostic tool not only for gastric GISTs but also for non-gastric GISTs, it will result in several advantages. First, EUS-AI is more feasible than EUS-FNAB for the diagnosis of duodenal SELs. Reports indicate that the diagnostic accuracy of EUS-FNAB for duodenal SELs is unsatisfactory owing to poor endoscope operability due to the unique duodenal anatomical structure of the narrow lumen and duodenal fold, although the malignant potential of duodenal GISTs is generally higher than that of gastric GISTs\textsuperscript{24}. Indeed, it is much easier to obtain EUS images for EUS-AI than for EUS-FNAB. Second, EUS-AI can be safely applied without an invasive sampling process such as EUS-FNAB, and the differential diagnosis of GISTs can be automatically made, which is expected to reduce the risk of adverse events such as bleeding and infection. Third, EUS-AI can be used at any institution without the need for special endoscopic techniques, such as EUS-FNAB. This should lead to the early diagnosis and treatment of non-gastric GISTs, which are highly malignant\textsuperscript{25}.

This study has some limitations. First, it was retrospective. Second, all EUS images were obtained from a single center. Third, the number of SELs was relatively small. Finally, we enrolled the case where the pathological diagnoses were made not only with surgical specimen but also with the samples obtained by EUS-FNAB or biopsy because the cases being diagnosed as benign tumors such as leiomyoma by EUS-FNAB or biopsy do not
undergo surgery. It might cause a bias, however, we consider it is acceptable since the diagnostic accuracy of EUS-FNAB or biopsy in our institution could be sufficiently high. A prospective multicenter study should be required to verify the findings of the present study.

In conclusion, an EUS-AI system based on gastric SELs demonstrated good diagnostic ability for non-gastric GISTs. This system is likely to contribute to the diagnosis of gastrointestinal SELs in the future.

### Methods

**Study design and inclusion/exclusion criteria.** This retrospective study was approved by the Kyushu University ethical review board on April 2021 (approval study number: 2021-190), and the requirement for obtaining written informed consent from patients was waived. All steps of this study were performed in accordance with relevant guidelines. A total of 225 SELs were included in this study, with the following inclusion criteria: patients with (a) non-gastric SELs who underwent EUS performed by EUS experts in our hospital between January 2015 and January 2021; (b) non-gastric SELs suspected to arise from the muscle layer of the gastrointestinal tract on EUS images, and (c) non-gastric SELs with available histopathological diagnoses. We excluded cases with poor-quality EUS images caused by air or strong artifacts.

**EUS images, lesion size, and pathological diagnosis.** All EUS images were acquired by EUS experts with at least 5 years of experience in EUS procedures using conventional echoendoscopes (GF-UE260-AL5, Table 2. Patient and lesion characteristics of esophageal, duodenal, and colonic lesions. Values are presented as n, median (range), or n (%). GIST, gastrointestinal stromal tumors.

| SEL location | Cases used to set the cutoff value | Cutoff values | Accuracy (%) | Sensitivity (%) | Specificity (%) | AUC |
|--------------|-----------------------------------|---------------|--------------|----------------|----------------|-----|
| Esophagus    | Esophageal                         | 0.997         | 100          | 100            | 100            | 1.0 |
|              | Gastric                           | 0.94          | 100          | 100            | 100            |     |
| Duodenum     | Duodenal                           | 0.93          | 96.2         | 100            | 0              | 0.96|
|              | Gastric                           | 0.94          | 96.2         | 100            | 0              |     |
| Colon        | Colonic                           | 0.93          | 90.9         | 100            | 0              | 0.80|
|              | Gastric                           | 0.94          | 90.9         | 100            | 0              |     |

Table 3. Diagnostic ability of EUS-AI according to cutoff values. AUC, area under the curve; EUS-AI, endoscopic ultrasound-based artificial intelligence; SEL, subepithelial lesion.
GF-UCT260, TGF-UC260J; Olympus Corporation, Tokyo, Japan) or mini-probes (UM-3R, UM-2R; Olympus Corporation). All echoendoscopes and mini-probes were used while they were connected to conventional EUS processors (Prosound SSD α-75 scanner, Prosound SSD α-5 scanner: Hitachi Aloka, Tokyo, Japan; EU-ME2; Olympus Corporation). The maximum diameter of the lesions was measured using the EUS images. The histological diagnoses of the specimens obtained from EUS-FNAB, endoscopic biopsy, or surgical operation were made by three pathologists, including at least one certified by the Japanese Society of Pathology. No interobserver disagreement between the pathologists was reported for the diagnosis of SELs used in this study.

**AI training and construction of the EUS-AI system.** The training method for the AI has been previously described. Briefly, EUS images from 173 cases with gastric SELs were prepared to train the AI according to the following procedures. Each EUS image was trimmed to only the lesion to allow the AI to recognize the lesions. A total of 2718 images from 173 SELs in 173 cases (1729 images in 112 cases with GIST and 989 images of 61 non-GISTs, including 43 leiomyomas, 7 schwannomas, 7 ectopic pancreases, 2 lipomas, and 2 inflammatory changes) were prepared for the training data set.

Inverted forms and rotated images were prepared, with the images being rotated at 15° intervals; each rotated image was saved as a new image. The EUS-AI system was created on an AI-specific computer containing a GeForce GTX 1080 graphics processing unit (NVIDIA, California, USA), a core i7-8700 central processing unit (Intel, California, USA), and a deep analyzer graphical user interface-based deep learning tool (GHELIA, Tokyo, Japan). Xception was selected as the CNN-based deep learning model, and an adaptive moment estimation (ADAM) algorithm was selected to optimize the learning procedure.

**Diagnostic ability of EUS-AI for non-gastric GISTs.** All EUS images for each case were supplied to the EUS-AI to make a diagnosis (Fig. 3). The EUS-AI estimated the probability that the lesion was a GIST on a scale of 0 to 1.0. The final diagnosis of GIST was made if the probability that the lesion was a GIST was higher than the cutoff value, which was set using the Youden index. The final diagnoses were assessed, and the diagnostic abilities of the EUS-AI system (accuracy, sensitivity, specificity, and area under the curve [AUC]) were evaluated. The diagnostic ability according to the AUC was defined as follows: 1.0–0.9 as high accuracy, 0.9–0.7 as moderate accuracy, and 0.7–0.5 as poor accuracy. All statistical analyses were performed using JMP software version 15.1 (SAS Institute, Cary, NC, USA). The diagnostic yield was also confirmed in cases where the postoperative patho-

Figure 2. Relationship between the diagnostic ability of EUS-AI for non-gastric GISTs and lesion size. (A,B) The relationship between the diagnostic accuracy of EUS-AI and lesion size in the 52 cases with non-gastric SELs (A), and in each part of the gastrointestinal tract (esophagus; n = 15, duodenum; n = 26, colon; n = 11) (B) was examined using a logistic regression model. The concordance rates between the diagnoses of the abovementioned conditions and pathological results were determined. The cases with colorectal SELs had missing values between 0 and 12 mm because of the insufficient number of cases. EUS-AI, endoscopic ultrasound-based artificial intelligence; GIST, gastrointestinal stromal tumors; SEL, subepithelial lesion.
logical diagnosis was made in addition to determination of the diagnostic yield of EUS-AI using all non-gastric SEL cases. In addition, we evaluated the diagnostic accuracy of EUS-FNAB for the SEL cases who underwent surgery after preoperative diagnosis had been made by EUS-FNAB to determine that the pathological diagnosis made by EUS-FNAB is reliable in this study.

Diagnostic ability of EUS-AI for non-gastric GISTs in parts of the gastrointestinal tract. To confirm whether there were any differences in the diagnostic ability of EUS-AI between the cutoff value set for each part of the gastrointestinal tract using the Youden index and that of the value set for the stomach (0.94) as we previously determined, the diagnostic abilities (accuracy, sensitivity, specificity, and AUC) calculated based on the two types of cutoff values were compared.

Relationship between lesion size and diagnostic ability. To evaluate the relationship between the diagnostic ability of EUS-AI and lesion size, a subanalysis was conducted using the test sets, via a logistic regression model in the JMP software. In the logistic regression model, the independent variable was whether the diagnosis was correct, while the lesion size was set as the dependent variable.

Data availability
Of the datasets generated and analyzed in this study, data to the extent permitted by the Kyushu University Ethical Review Board are available from the corresponding authors upon reasonable request.

Received: 26 February 2022; Accepted: 20 September 2022
Published online: 05 October 2022

References
1. Hedenbro, J. L., Ekelund, M. & Wetterberg, P. Endoscopic diagnosis of submucosal gastric lesions. The results after routine endoscopy. Surg. Endosc. 5, 20–23 (1991).
2. Nishida, T. & Hirota, S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol. Histopathol. 15, 1293–1301 (2000).
3. Crosby, J. A. et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann. Surg. Oncol. 8, 50–59 (2001).
4. Casali, P. G. et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, iv267 (2018).
5. Faulx, A. L. et al. The role of endoscopy in subepithelial lesions of the GI tract. Gastrointest. Endosc. 85, 1117–1132 (2017).
6. Nishida, T., Blay, J. Y., Hirota, S., Kitagawa, Y. & Kang, Y. K. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 19, 3–14 (2016).
7. Yoshinaga, S., Hilmi, I. N., Kwek, B. E., Hara, K. & Goda, K. Current status of endoscopic ultrasound for the upper gastrointestinal tract in Asia. Dig. Endosc. 27(Suppl 1), 1–20 (2015).
8. Minoda, Y. et al. Superiority of mucosal incision-assisted biopsy over ultrasound-guided fine needle aspiration biopsy in diagnosing small gastric subepithelial lesions: A propensity score matching analysis. BMC Gastroenterol. 20, 19 (2020).
9. Fernández-Esparraz, G. et al. Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: A randomized crossover study. Endoscopy 42, 292–299 (2010).
10. Osoegawa, T. et al. Mucosal incision-assisted biopsy versus endoscopic ultrasound-guided fine-needle aspiration with a rapid on-site evaluation for gastric subepithelial lesions: A randomized cross-over study. Dig. Endosc. 31, 413–421 (2019).
11. Minoda, Y. et al. The efficacy and safety of a promising single-channel endoscopic closure technique for endoscopic treatment-related artificial ulcers: A pilot study. Gastrointest. Tumors 7, 21–29 (2020).
12. Fujioka, T. et al. Distinction between benign and malignant breast masses at breast ultrasound using deep learning method with convolutional neural network. Jpn. J. Radiol. 37, 466–472 (2019).
13. Han, S. et al. A deep learning framework for supporting the classification of breast lesions in ultrasound images. Phys. Med. Biol. 62, 7714–7728 (2017).
14. Mori, Y. et al. Cost savings in colonoscopy with artificial intelligence-aided polyp diagnosis: An add-on analysis of a clinical trial (with video). Gastrointest. Endosc. 92, 905–911.e1 (2020).
15. Kudo, S. E. et al. Artificial intelligence-assisted system improves endoscopic identification of colorectal neoplasms. Clin. Gastroenterol. Hepatol. 18, 1874-1881.e2 (2020).
16. Minoda, Y. et al. Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gastrointestinal stromal tumors. *J. Gastroenterol.* **55**, 1119–1126 (2020).
17. Miettinen, M., Majidi, M. & Lasota, J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. *Eur. J. Cancer* **38**(Suppl 5), S39–S51 (2002).
18. Kim, Y. H. et al. Application of a convolutional neural network in the diagnosis of gastric mesenchymal tumors on endoscopic ultrasonography images. *J. Clin. Med.* **29**, 3162 (2020).
19. Chang Kyo, Oh. et al. Convolutional neural network-based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images. *J. Gastroenterol. Hepatol.* **36**, 3387–3394 (2021).
20. Seven, G. et al. Differentiating gastrointestinal stromal tumors from leiomyomas using a neural network trained on endoscopic ultrasonography images. *Dig. Dis.* **40**, 427–435 (2022).
21. Seo, S. W. et al. Accuracy of a scoring system for the differential diagnosis of common gastric subepithelial tumors based on endoscopic ultrasonography. *J. Dig. Dis.* **14**, 647–653 (2013).
22. Yegin, E. G. & Duman, D. G. Small EUS-suspected gastrointestinal stromal tumors of the stomach: An overview for the current state of management. *Endosc. Ultrason* **5**, 69–77 (2016).
23. Tateishi, U., Hasegawa, T., Satake, M. & Moriyama, N. Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality. *J. Comput. Assist. Tomogr.* **27**, 792–798 (2003).
24. Sepe, P. S., Moparty, B., Pitman, M. B., Saltzman, J. R. & Brugge, W. R. EUS-guided FNA for the diagnosis of GI stromal cell tumors: Sensitivity and cytologic yield. *Gastrointest. Endosc.* **70**, 254–261 (2009).
25. Miettinen, M. & Lasota, J. Gastrointestinal stromal tumors: Pathology and diagnosis at different sites. *Semin. Diagn. Pathol.* **23**, 70–83 (2006).

**Acknowledgements**

We thank Dr. Junji Kishimoto of the Kyushu University Center for Clinical and Translational Research for assisting with the statistical analyses. This work was supported in part by The National Cancer Center Research and Development Fund (2020-A-12).

**Author contributions**

Y.M. designed the study, analyzed the data, and wrote the manuscript. E.I. collected the data and critically reviewed the manuscript. The other authors contributed to the data collection. All authors have read and approved the manuscript.

**Competing interests**

E.I. received lecture fees from Takeda Pharmaceutical Co., Ltd., and belongs to an endowed course supported by companies including Ono Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Fujifilm Medical Co., Ltd., Terumo Corporation, FANCL Corporation, Ohga Pharmacy, and Abbott Japan, LLC. E.I. received a lecture honorarium from Takeda Pharmaceutical Company. Y.O. conducted collaborative research with Fujifilm Medical Co., Ltd. and FANCL Corporation. All other authors declare no conflicts of interest associated with this study.

**Additional information**

**Correspondence** and requests for materials should be addressed to E.I.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note**  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access]  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022